From the FDA Drug Label
2.1 Dosage The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. The 2. 5 mg dosage is for treatment initiation and is not intended for glycemic control. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.
The prescription for a 3-month supply of Mounjaro (tirzepatide) 2.5mg weekly is 13 doses because the initial dose of 2.5mg is only for the first 4 weeks, after which the dose is increased to 5mg. However, the question specifically asks for the 2.5mg dose.
- Dose: 2.5mg
- Frequency: once weekly
- Duration: 3 months (approximately 13 weeks)
- Number of doses: 13 doses 1 1
From the Research
Prescription Information for Mounjaro (Tirzepatide)
- The studies provided do not include specific information on the prescription for a 3-month supply of Mounjaro (tirzepatide) 2.5mg weekly 2, 3, 4, 5, 6.
- However, the studies mention that tirzepatide is administered via once-weekly subcutaneous injection, with doses ranging from 5mg to 15mg in clinical trials 2, 3, 4, 5.
- The dosage of 2.5mg is not explicitly mentioned in the provided studies, but it is likely that the prescription would be based on the patient's individual needs and medical history.
- It is recommended to consult the prescribing information and guidelines for Mounjaro (tirzepatide) for specific dosage and administration instructions.
Clinical Trials and Studies
- The SURPASS clinical trial program assessed the efficacy and safety of tirzepatide in adults with type 2 diabetes, with doses of 5mg, 10mg, and 15mg 2, 3, 5.
- The studies demonstrated significant reductions in HbA1c and body weight, as well as improvements in cardiovascular risk factors 2, 3, 5.
- Tirzepatide was found to be well-tolerated, with a low risk of hypoglycemia and a similar safety profile to other GLP-1 receptor agonists 2, 3, 5.